| Volume: | 1,871,057 |
|---|---|
| Day's Low: | $11.90 |
| 52-wk Low: | $5.50 |
| Previous Close: | $12.03 |
| Dividend: | $0.00 |
| Market Cap: | 1,704,000 |
| Avg Volume: | 3,197,000 |
|---|---|
| Day's High: | $12.12 |
| 52-wk High: | $15.69 |
| Open Price: | $11.90 |
| Yield: | 0.00% |
| P/E (Forward): | NA |
| 4:48 PM | 11/2/2009 | UPDATE:FDA Approves New Byetta Label Amid Renal-Failure Reports |
| 8:19 AM | 10/29/2009 | UPDATE: Roche's New Diabetes Drug Works Better Than Byetta |
| 4:48 AM | 10/29/2009 | Roche: New Diabetes Drug Works Better Than Byetta - Study |
| 9:58 PM | 10/19/2009 | Galleon Holdings Include OSI Pharmaceuticals, Huron Consulting |
| 5:06 PM | 10/19/2009 | 2ND UPDATE:Galleon Holdings Include OSI Pharma,Huron Consulting |
| 4:02 PM | 10/19/2009 | UPDATE: Galleon Holdings Include OSI Pharma, Huron Consulting |
| 11/2/2009 | Stocks in the Spotlight Monday |
| 11/2/2009 | Monday's biggest gaining and declining stocks |
| 11/2/2009 | Human Genome, Vertex, Amylin in play |
| 10/30/2009 | Drug stocks slip; Ipsen gains for second day |
| 10/19/2009 | OSI, Huron Among Galleon Holdings |
| 10/5/2009 | Fund Doubles Amylin Stake |
| 9/25/2009 | Another Diabetes Drug is Linked to Pancreas Inflammation |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | -0.19 | -0.46 | 58.70 |
| EPS, GAAP | -0.19 | -0.57 | 66.67 |
| Consensus Estimate | -0.30 | -0.51 | 41.18 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | -1.25 | -1.80 | 30.56 |
| EPS, GAAP | -2.11 | -2.12 | 0.47 |
| Consensus Estimate | -1.51 | NA | NA |
| AMLN | Industry Average | |
| P/E (TTM) | -5.72 | 185.00 |
| P/E (Forward) | NA | -21.30 |
| PEG Ratio | NA | -1.08 |
| Price/Sales | 2.06 | 4.67 |
| Beta | 1.55 | 1.72 |